Protalix BioTherapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
23 August 2018 - 9:00PM
GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX,
TASE:PLX), a biopharmaceutical company focused on the development
and commercialization of recombinant therapeutic proteins expressed
through its proprietary plant cell-based expression system,
ProCellEx®, today announced that the Company will present at the
20th Annual Rodman & Renshaw Global Investment Conference,
sponsored by H.C. Wainwright & Co., LLC. The conference
is being held on September 4-6, 2018 at the St. Regis New York
Hotel in New York City.
Mr. Moshe Manor, the Company’s President and Chief Executive
Officer, will provide a corporate overview on Wednesday, September
5 at 2:10 pm ET and will be available to participate in one-on-one
meetings with investors who are registered to attend the
conference.
If you are an institutional investor, and would like to attend
the Company’s presentation, please click on the following link
(www.rodmanevents.com) to register for the conference. Once
your registration is confirmed, you will be prompted to log into
the conference website to request a one-on-one meeting with the
Company.
A live and archived webcast of the presentation will be
available at www.protalix.com, on the event calendar page.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the
development and commercialization of recombinant therapeutic
proteins expressed through its proprietary plant cell-based
expression system, ProCellEx®. Protalix’s unique expression
system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner.
Protalix’s first product manufactured by ProCellEx, taliglucerase
alfa, was approved for marketing by the U.S. Food and Drug
Administration (FDA) in May 2012 and, subsequently, by the
regulatory authorities of other countries. Protalix has
licensed to Pfizer Inc. the worldwide development and
commercialization rights for taliglucerase alfa, excluding Brazil,
where Protalix retains full rights. Protalix’s development
pipeline includes the following product candidates: pegunigalsidase
alfa, a modified version of the recombinant human alpha-GAL-A
protein for the treatment of Fabry disease; OPRX-106, an
orally-delivered anti-inflammatory treatment; alidornase alfa for
the treatment of Cystic Fibrosis; and others. Protalix
partnered with Chiesi Farmaceutici S.p.A., both in the United
States and outside the United States, for the development and
commercialization of pegunigalsidase alfa.
Investor Contact
Marcy Nanus, Managing Director Solebury Trout 646-378-2927
mnanus@soleburytrout.com
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Apr 2024 to May 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From May 2023 to May 2024